Terfenadine and brompheniramine maleate in urticaria and dermographism.
The effects of brompheniramine maleate (12 mg twice daily in sustained release form) and terfenadine (60 mg twice daily) on the symptoms and well-being of 16 adults with urticaria with or without dermographism were assessed by symptom questionnaire. Following an initial 2-week period without therapy, each drug was taken for 2 weeks in a randomised double-blind cross-over study. Both drugs produced significant relief of itch and rash but only brompheniramine produced significant drowsiness. Brompheniramine maleate was more effective than terfenadine in the patients with dermographism.
D000328:Adult; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001977:Brompheniramine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D011897:Random Allocation; D016593:Terfenadine; D014581:Urticaria / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D011725:Pyridines; D016593:Terfenadine; D001977:Brompheniramine